| 000 | 01670 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516115758.0 | ||
| 264 | 0 | _c20130107 | |
| 008 | 201301s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1684/bdc.2012.1641 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKhaled, Wassef | |
| 245 | 0 | 0 |
_a[Non oncologic applications of molecular targeted therapies]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cOct 2012 |
||
| 300 |
_a953-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aDrug-Eluting Stents |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aMacular Degeneration _xdrug therapy |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xdrug therapy |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 700 | 1 | _ade la Motte Rouge, Thibault | |
| 700 | 1 | _aAmirault, Jean-Christophe | |
| 700 | 1 | _aVignot, Stéphane | |
| 773 | 0 |
_tBulletin du cancer _gvol. 99 _gno. 10 _gp. 953-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1684/bdc.2012.1641 _zAvailable from publisher's website |
| 999 |
_c22207553 _d22207553 |
||